FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma
Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Antibiotics Prevent Fevers, Death in Newly Diagnosed Myeloma Patients, Study Says
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a…
Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership
A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including…
EMA Reviewing Belantamab Mafodotin for Heavily Pretreated Multiple Myeloma
The European Medicines Agency has agreed to review the application of  GlaxoSmithKline‘s belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company…
Takeda, Snow Myeloma App ‘Being Patient’ Wins Pharma Choice Award
Takeda and Snow Companies won one of the top prizes in PM360’s annual Pharma Choice Awards for an app aimed at…
Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma
Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy Reolysin (pelareorep) and Kyprolis (carfilzomib) provides benefits…
